Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Serprozyme ApS
APS
Active
CVR 44083205
Ølstvadbrovej 31
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2023
— employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
DKK 31K
-1469% vs 2023
EBITDA margin
100.0%
+1469% vs 2023
Equity ratio
90.1%
Financial strength
Net profit 2024
DKK 25K
+1222% vs 2023
EBITDA — year on year
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
DKK 31K
-1469%
EBITDA
DKK 31K
+1469%
Net profit
DKK 25K
+1222%
Total assets
DKK 69K
+83%
Equity
DKK 62K
+65%
Employees
—
—
Company information
Legal name
Serprozyme ApS
CVR number
44083205
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
26. maj 2023
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør
Company purpose
Selskabets formål er at drive virksomhed med handel og service, samt enhver i forbindelse hermed stående virksomhed.
Contact
Address
Ølstvadbrovej 31
Phone
+4541112177
Email
contact@serprozyme.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Randers
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
Income statement
DKK thousands
Item
2023
2024
Revenue
-2
31
Staff expenses
-0
-0
EBITDA
-2
31
Depreciation & amort.
-0
-0
EBIT
-2
31
Net financials
0
0
Profit before tax
-2
31
Tax
-0
7
Net profit
-2
25
Balance sheet
DKK thousands
Item
2023
2024
Total assets
38
69
Equity
38
62
Long-term debt
0
0
Short-term debt
0
7
Total debt
0
7
Financial ratios
5-year trend
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
2023
2024
Equity ratio
90.1%
This company
38.2%
Market median
+136% vs market
2023
2024
Return on equity
39.3%
This company
18.4%
Market median
+114% vs market
2023
2024
Net profit margin
79.0%
This company
8.1%
Market median
+875% vs market
2023
2024
Asset turnover
0.45×
This company
1.12×
Market median
-60% vs market
2023
2024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-05-26 – 2023-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
DM
Daniel Miotto Dupont
Founder
Founder
2023
—
—
JK
Jan Kristian Jensen
Chief Executive Officer
Chief Executive Officer
2023
—
—
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Emvijo Initiative ApS
Company
50.0%
50.0%
2023
Jan Kristian Jensen Holding ApS
Company
50.0%
50.0%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Emvijo Initiative ApS
Serprozyme ApS
(this company)
Board network connections
Board members of Serprozyme ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Daniel Miotto Dupont
Founder
0 companies
Jan Kristian Jensen
Chief Executive Officer
0 companies